Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Future Med Chem. 2012 Sep;4(13):1751–1761. doi: 10.4155/fmc.12.124

Table I.

Alzheimer’s disease drugs and selected compounds in various stages of clinical trials.

Compound Trade name Source Pathway Status Year of approval
(US FDA)
Tacrine Cognex® Synthetic AChE inhibitors Market 1993
Donepezil Aricept® Synthetic AChE inhibitors Market 1996
Rivastigmine Exelon® Synthetic (natural product-inspired) AChE inhibitors Market 2000
Galantamine Razadyne® Natural product (plant) AChE inhibitors Market 2001
Memantine Axura®, Namenda®, Abixa® and Memox Synthetic N-methyl-d-aspartate receptor antagonist Market 2004
Curcumin Natural product (plant) Aβ plaques Phase II
Homotaurine Alzhamed™ Natural product (algae) Aβ plaques Phase III (failed)
R-flurbiprofen Flurizan™ Synthetic Aβ plaques Phase III (failed)
Minocycline Synthetic (natural product-inspired) Aβ/tau/microglia Phase II
Methylene blue Rember™ Synthetic Tau aggregation Phase II
Tideglusib Zentylor™ Synthetic Tau aggregation Phase II

Data taken from [27,201].

HHS Vulnerability Disclosure